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Vienna, AustriaDuc H. Le1. Collagen-Speciﬁc T-Cell Repertoire as a New Biomarker for
Rheumatoid Arthritis
HLA-DRB1 gene variants are known risk factors for several immuno-
logical diseases. Patients with rheumatoid arthritis (RA) often carry
HLA-DRB1*04 (DR4+), and have a repertoire of collagen IIp261-273-
speciﬁc T cells in the peripheral blood at the onset of the disease.
Gabriele Di Sante (Rome, Italy) and colleagues enrolled 90 patients
with early RA to determine whether this subset of DR4-restricted
collagen-speciﬁc T cells could represent new markers of severity of
the disease and response to therapy. The authors examined the usage
of T-cell receptor (TCR)-beta chains in peripheral blood mononuclear
cells cultured with or without the human collagen II peptide p261-
273. They found that the presence of T cells carrying TCR-beta chains
TRBV25 and TRBV6_4was correlated toHLA-DR and RA disease activity,
and the detection of TRBV25 T cells could predict active disease in
DR4+ patients. HLA-DRB1*04/04, 04/01 and 04/11 alleles were signiﬁ-
cantly associated with TRBV25 usage, higher disease activity at RA
onset, and poor response to disease-modifying anti-rheumatic drugs.
The ﬁndings could help predict the course of RA and tailor treatments
for RA patients.
2. Exposure to BCG Leads to NK Cell Priming for Better Recognition
of Bladder Cancer Cells
The tuberculosis vaccine Bacillus Calmette-Guérin (BCG) is used
as intravesical immunotherapy to treat non-muscle-invasive
bladder cancer and help prevent recurrence. To test how BCG may
interact with bladder cancer cells and natural killer (NK) cells,
Eva M. García-Cuesta, Gloria Esteso and collaborators (Madrid,
Spain) incubated peripheral blood mononuclear cells from healthy
donors with BCG, and analyzed changes in NK cell phenotype
and cytotoxic function against several bladder cancer cell lines. In-
cubation with BCG resulted in vigorous proliferation of CD56bright
NK cells that initially produced IFNγ in response to bladder cancer
cells and later made cytotoxic responses. The researchers also
analyzed soluble factors in the urine of bladder cancer patients
treated with BCG or mitomycin and showed that the cytokines
present in urine of BCG-treated patients belonged to an ‘innate-im-
mune’ type of response. The authors concluded that BCG can
activate NK cells and promote a better recognition of bladder
cancer cells.http://dx.doi.org/10.1016/j.ebiom.2015.10.006
2352-3964/© 2015 The Author. Published by Elsevier B.V. This is an open access article under3. Role of Ets-2 and FoxP3 in Multiple Sclerosis Pathogenesis
Multiple sclerosis (MS) is characterized by autoimmune myelin
damage, in which pathogenic Th1 and Th17 cells may play a role.
Ets-2 and FoxP3 are transcriptional silencers of naive Th effectors
(Teffs) and Tregs, and they suppress cytokine gene expression by bind-
ing to ARRE-2 promoter element. In this study, Ioannis Panagoulias
(Patras, Greece) and colleagues analyzed the expression of Ets-2 and
FoxP3 in Th cells isolated from MS patients and age/sex-matched
healthy controls. The authors found that the median % of activated
Teffs and Tregs were 2.89 and 0.56 in the acute phase of MS, and 0.8
and 2.37 in remission phase (vs 0.04 and 2.87 in controls). In MS
patients, Teffs and Tregs showed very low levels of Ets-2 and FoxP3
synthesis and immunopositivity in the nucleus; ChIP analysis also
revealed no Ets-2 binding and very weak FoxP3 binding to ARRE-2
(vs controls). Signiﬁcantly higher expression of IL-2 and IL-17A in
naive Teffs, TNFα in memory Teffs, and IL-2 and IFNγ in Tregs were
also seen inMS patients. The authors concluded that low-level synthesis
and dysfunction of Ets-2 and FoxP3 in Th cells of MS patients are prob-
ably responsible for the increase in pathological Th1 and Th17 cell
clones, leading to MS pathogenesis.
4. DARC Gene Polymorphism Associated with Total Joint
Replacement Failure
Prosthesis failure is not uncommon in patients with total joint re-
placement (TJR), with unknown genetic risk factors. Petra Schneiderova
(Olomouc, Czech Republic) and collaborators divided 354 TJR patients
into those with complications (either aseptic loosening [AL, n = 110];
or prosthetic joint infection [PJI, n = 126]) and control group without
complications for at least 10 years (n = 118). The authors genotyped
11 single nucleotide polymorphisms (SNPs) that are known to affect
serum levels of several pro-inﬂammatory molecules (IL-6, CCL2/MCP-
1, and CRP) and erythrocyte sedimentation rate (ESR). They found
only one SNP, rs12075*G allele, which was present more frequently in
patientswith complications (46.6%) compared to thosewithout compli-
cations (36.0%, p = 0.007, OR = 1.55, 95% CI = 1.13–2.14). This allele
was found more in patients with AL (49.5%), and less so in patients
with PJI (44.0%). rs12075 is located in the gene DARC (Duffy antigen re-
ceptor for chemokines). This study suggested the allele rs12075*G,
which is linked to lower serum levels of CCL2/MCP-1, as a genetic risk
factor for prosthesis failure (especially AL).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1267D.H. Le / EBioMedicine 2 (2015) 1266–12675.Hsp72 as a Potential Autoantigen in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary ﬁbrosis (IPF) is a poorly understood intersti-
tial lung disease. In this study, Ross Mills (Edinburgh, UK) and
colleagues aimed to elucidate the role of the recently identiﬁed heat
shock protein 72 (Hsp72) in IPF pathogenesis. They screened for
Hsp72 and anti-Hsp72 antibodies in the serum and brochoalveolar
lavage ﬂuid (BALF) of IPF patients. Signiﬁcantly higher concentration
of Hsp72 was found in the serum of IPF patients compared to controls
(p ≤ 0.0001), with no difference in BALF (p = 0.0577). Using ELISA,the research group found no signiﬁcant difference in anti-Hsp72 anti-
bodies in the serum of IPF patients compared to controls (p =
0.8286). However, they found a signiﬁcantly higher concentration of
anti-Hsp72 antibodies in the BALF of patients compared to controls
(p ≤ 0.0001), with a signiﬁcant difference between progressors and
non-progressors among IPF patients (p=0.0080), suggesting a possible
role in outcome prognosis by measuring BALF anti-Hsp72 antibodies.
The ﬁndings further support the hypothesis that Hsp72 dysregulation
may be involved in IPF pathogenesis.
